Robert Chess Sells 5,000 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the sale, the director now directly owns 16,641 shares of the company’s stock, valued at $832,050. The trade was a 23.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Robert Chess also recently made the following trade(s):

• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The stock was sold at an average price of $51.85, for a total value of $181,682.40.
• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The stock was sold at an average price of $47.26, for a total value of $170,136.00.

Twist Bioscience Stock Down 3.4 %

Shares of NASDAQ:TWST traded down $1.52 during midday trading on Friday, reaching $43.60. The company’s stock had a trading volume of 803,345 shares, compared to its average volume of 651,469. The firm has a market capitalization of $2.59 billion, a PE ratio of -12.11 and a beta of 1.85. The stock has a fifty day moving average of $46.35 and a 200 day moving average of $46.46. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. boosted its stake in shares of Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock worth $9,301,000 after buying an additional 82,953 shares during the last quarter. Oddo BHF Asset Management Sas acquired a new position in Twist Bioscience in the third quarter valued at approximately $3,302,000. Beaird Harris Wealth Management LLC purchased a new stake in Twist Bioscience in the 3rd quarter worth approximately $95,000. Franklin Resources Inc. grew its stake in shares of Twist Bioscience by 3.4% during the 3rd quarter. Franklin Resources Inc. now owns 252,064 shares of the company’s stock worth $11,756,000 after purchasing an additional 8,308 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience during the 3rd quarter valued at approximately $34,000.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on TWST shares. TD Cowen reaffirmed a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Wolfe Research began coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Finally, Scotiabank raised their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.